On July 29, 2014 ImmuNext reported that it has extended and expanded its collaboration with Janssen Biotech, Inc., focused on the development of novel therapeutics that modulate the immune system for the treatment of cancer (Press release ImmuNext, JUL 29, 2014, http://immunext.com/news.php [SID:1234500870]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ImmuNext has extended its collaborative effort with Janssen to carry out research and development of cancer therapeutics that antagonize the VISTA signaling pathway. VISTA is a novel negative checkpoint regulator. Janssen will be responsible for clinical development and commercialization of all products under the agreement.

In addition, ImmuNext has expanded the collaboration with Janssen to now include discovery of new targets for modulation of the immune system for the treatment of cancer.

"We have made great progress in our collaboration with Janssen, a global leader in the field of oncology, and we look forward to continuing our collaborative efforts to develop innovative immunotherapies to improve the lives of cancer patients," commented David DeLucia, ImmuNext’s chief executive officer.